{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:48:28Z","timestamp":1794541708818,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-05267-4","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T01:24:07Z","timestamp":1786411447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of BAFF\/APRIL-pathway inhibitors versus placebo in adults with IgA nephropathy: a systematic review with pairwise and network meta-analysis"],"prefix":"10.1186","volume":"27","author":[{"given":"Nada","family":"Mansour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy M. F.","family":"Elbarody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-5998","authenticated-orcid":false,"given":"Ahmed M.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"issue":"2","key":"5267_CR1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.amjms.2020.10.003","volume":"361","author":"A Rajasekaran","year":"2021","unstructured":"Rajasekaran A, Julian BA, Rizk DV. IgA nephropathy: an interesting autoimmune kidney disease. Am J Med Sci [Internet]. 2021;361(2):176\u201394. Available from: https:\/\/doi.org\/10.1016\/j.amjms.2020.10.003. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962920304353.","journal-title":"Am J Med Sci"},{"key":"5267_CR2","doi-asserted-by":"publisher","first-page":"1436923","DOI":"10.3389\/fimmu.2024.1436923","volume":"15","author":"EJ Filippone","year":"2024","unstructured":"Filippone EJ, Gulati R, Farber JL. Contemporary review of IgA nephropathy. Front Immunol [Internet]. 2024;15:1436923. Available from: https:\/\/doi.org\/10.3389\/fimmu.2024.1436923. https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1436923.","journal-title":"Front Immunol"},{"key":"5267_CR3","doi-asserted-by":"publisher","first-page":"1346769","DOI":"10.3389\/fneph.2023.1346769","volume":"3","author":"CK Cheung","year":"2023","unstructured":"Cheung CK, Barratt J, Liew A, et al. The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies. Front Nephrol. 2023;3:1346769.","journal-title":"Front Nephrol"},{"key":"5267_CR4","doi-asserted-by":"crossref","unstructured":"Dong Y, Shen X, Jin H, et al. Epigenetic regulation in the pathogenesis of renal inflammation: insights and therapeutic potentials. iNew med [Internet]. 2025, Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/inm3.70012.","DOI":"10.1002\/inm3.70012"},{"key":"5267_CR5","doi-asserted-by":"crossref","unstructured":"Gong X, Wang Z, Yang S, et al. The role of endothelin-1 in autoimmune diseases: mechanistic insights and therapeutic targets. iNew Med [Internet]. 2026;2. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/inm3.70042.","DOI":"10.1002\/inm3.70042"},{"key":"5267_CR6","doi-asserted-by":"crossref","unstructured":"Liu J, Nanayakkara GK, Lu Y, et al. A new paradigm: 46 structural cell types function as environment-supporting innate immune cells, with endothelial and vascular smooth muscle cells as key prototypes. iNew Med [Internet]. 2026, Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/inm3.70050.","DOI":"10.1002\/inm3.70050"},{"key":"5267_CR7","doi-asserted-by":"publisher","unstructured":"Rovin BH, Adler SG, Barratt J, et al. KDIGO, 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):S1\u2013276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021.","DOI":"10.1016\/j.kint.2021.05.021"},{"issue":"1","key":"5267_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Toto RD, Stef\u00e1nsson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int [Internet]. 2021;100(1):215\u201324. Available from: https:\/\/doi.org\/10.1016\/j.kint.2021.03.033. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253821003963.","journal-title":"Kidney Int"},{"issue":"10417","key":"5267_CR9","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402(10417):2077\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(23)02302-4.","journal-title":"Lancet"},{"issue":"10405","key":"5267_CR10","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, Floege J, Tesa\u0159 V, Trimarchi H, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgard): 2-year results from a randomised phase 3 trial. Lancet. 2023;402(10405):859\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(23)01554-4.","journal-title":"Lancet"},{"issue":"3","key":"5267_CR11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.ajkd.2016.02.042","volume":"68","author":"LA Inker","year":"2016","unstructured":"Inker LA, Mondal H, Greene T, et al. Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am J Kidney Dis [Internet]. 2016;68(3):392\u2013401. Available from: https:\/\/doi.org\/10.1053\/j.ajkd.2016.02.042. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638616002146.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"5267_CR12","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/ASN.2016060640","volume":"28","author":"RA Lafayette","year":"2017","unstructured":"Lafayette RA, Canetta PA, Rovin BH, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol [Internet]. 2017;28(4):1306\u201313. Available from: https:\/\/doi.org\/10.1681\/ASN.2016060640. https:\/\/journals.lww.com\/00001751-201704000-00033.","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"5267_CR13","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1056\/NEJMoa2514415","volume":"394","author":"J Lv","year":"2026","unstructured":"Lv J, Liu L, Wang W, et al. Telitacicept for IgA nephropathy - interim analysis of a phase 3 trial. N Engl J Med. 2026;394(19):1916\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2514415.","journal-title":"N Engl J Med"},{"issue":"7","key":"5267_CR14","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2512133","volume":"394","author":"V Perkovic","year":"2026","unstructured":"Perkovic V, Trimarchi H, Tesar V, et al. Sibeprenlimab in IgA nephropathy-interim analysis of a phase 3 trial. N Engl J Med [Internet]. 2026;394(7):635\u201346. Available from: https:\/\/doi.org\/10.1056\/NEJMoa2512133. http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2512133.","journal-title":"N Engl J Med"},{"issue":"7","key":"5267_CR15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1056\/NEJMoa2510198","volume":"394","author":"R Lafayette","year":"2026","unstructured":"Lafayette R, Barbour SJ, Brenner RM, et al. A phase 3 trial of atacicept in patients with IgA nephropathy. N Engl J Med. 2026;394(7):647\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2510198.","journal-title":"N Engl J Med"},{"issue":"1","key":"5267_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA, 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev [Internet]. 2021;10(1):89. Available from: https:\/\/doi.org\/10.1186\/s13643-021-01626-4. https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-021-01626-4.","journal-title":"Syst Rev"},{"issue":"11","key":"5267_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384. https:\/\/doi.org\/10.7326\/M14-2385.","journal-title":"Ann Intern Med"},{"issue":"1","key":"5267_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14(1):135. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"5267_CR19","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/jrsm.1429","volume":"11","author":"J Shi","year":"2020","unstructured":"Shi J, Luo D, Weng H, et al. Optimally estimating the sample standard deviation from the five-number summary. Res Synth Methods [Internet]. 2020;11(5):641\u201354. Available from: https:\/\/doi.org\/10.1002\/jrsm.1429. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jrsm.1429.","journal-title":"Res Synth Methods"},{"issue":"9","key":"5267_CR20","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1177\/0962280219889080","volume":"29","author":"S McGrath","year":"2020","unstructured":"McGrath S, Zhao XF, Steele R, et al. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Stat Methods Med Res. 2020;29(9):2520\u201337. https:\/\/doi.org\/10.1177\/0962280219889080.","journal-title":"Stat Methods Med Res"},{"key":"5267_CR21","unstructured":"Higgins JPT, Li T, Deeks JJ. Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5. Cochrane; 2024. Available from: https:\/\/www.cochrane.org\/handbook."},{"issue":"17","key":"5267_CR22","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1002\/sim.1525","volume":"22","author":"H Quan","year":"2003","unstructured":"Quan H, Zhang J. Estimate of standard deviation for a log-transformed variable using arithmetic means and standard deviations. Stat Med. 2003;22(17):2723\u201336. https:\/\/doi.org\/10.1002\/sim.1525.","journal-title":"Stat Med"},{"issue":"2","key":"5267_CR23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1177\/1094428106291059","volume":"11","author":"SB Morris","year":"2008","unstructured":"Morris SB. Estimating effect sizes from pretest-posttest-control group designs. Organ Res Methods [Internet]. 2008;11(2):364\u201386. Available from: https:\/\/doi.org\/10.1177\/1094428106291059. https:\/\/journals.sagepub.com\/doi\/10.1177\/1094428106291059.","journal-title":"Organ Res Methods"},{"issue":"2","key":"5267_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3102\/10769986006002107","volume":"6","author":"LV Hedges","year":"1981","unstructured":"Hedges LV. Distribution theory for Glass\u2019s estimator of effect size and related estimators. J Educ Stat [Internet]. 1981;6(2):107. Available from: https:\/\/doi.org\/10.3102\/10769986006002107. https:\/\/www.jstor.org\/stable\/1164588?origin=crossref.","journal-title":"J Educ Stat"},{"issue":"9","key":"5267_CR25","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/sim.1761","volume":"23","author":"MJ Sweeting","year":"2004","unstructured":"Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med [Internet]. 2004;23(9):1351\u201375. Available from: https:\/\/doi.org\/10.1002\/sim.1761. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/sim.1761.","journal-title":"Stat Med"},{"key":"5267_CR26","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019;366:l4898. Available from: https:\/\/doi.org\/10.1136\/bmj.l4898. https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"issue":"3","key":"5267_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw [Internet]. 2010;36(3):1\u201348. Available from: https:\/\/doi.org\/10.18637\/jss.v036.i03. http:\/\/www.jstatsoft.org\/v36\/i03\/.","journal-title":"J Stat Softw"},{"issue":"7414","key":"5267_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ [Internet]. 2003;327(7414):557\u201360. Available from: https:\/\/doi.org\/10.1136\/bmj.327.7414.557. http:\/\/www.bmj.com\/cgi\/doi\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"4","key":"5267_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol [Internet]. 2011;64(4):401\u201306. Available from: https:\/\/doi.org\/10.1016\/j.jclinepi.2010.07.015. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089543561000332X.","journal-title":"J Clin Epidemiol"},{"key":"5267_CR30","doi-asserted-by":"publisher","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med [Internet]. 2020;17(4):e1003082. Available from: https:\/\/doi.org\/10.1371\/journal.pmed.1003082. https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003082.","DOI":"10.1371\/journal.pmed.1003082"},{"issue":"4","key":"5267_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Heal [Internet]. 2019;22(4):153\u201360. Available from: https:\/\/doi.org\/10.1136\/ebmental-2019-300117. https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Heal"},{"key":"5267_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol [Internet]. 2015;15:58. Available from: https:\/\/doi.org\/10.1186\/s12874-015-0060-8. https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-015-0060-8.","journal-title":"BMC Med Res Methodol"},{"key":"5267_CR33","unstructured":"R Core Team. R: a language and environment for statistical computing [internet]. R A Lang. Environ Stat Comput R found Stat Comput. 2024. Available from: https:\/\/www.r-project.org\/. Vienna, Austria."},{"key":"5267_CR34","unstructured":"Vertex Pharmaceuticals. Vertex announces positive week 36 interim analysis results from the phase 3 RAINIER study of povetacicept in IgA nephropathy [Internet]. 2026. Available from: https:\/\/news.vrtx.com\/news-releases\/news-release-details\/vertex-announces-positive-week-36-interim-analysis-results."},{"key":"5267_CR35","unstructured":"Anthera Pharmaceuticals Anthera announces top line final data from the extension period of the phase 2 BRIGHT-SC study of blisibimod in patients with IgA nephropathy Nasdaq: ANTH [internet]. Globe newswire. 2017. Available from: https:\/\/www.globenewswire.com\/news-release\/2017\/08\/28\/1101012\/0\/en\/Anthera-Announces-Top-Line-Final-Data-from-the-Extension-Period-of-the-Phase-2-BRIGHT-SC-Study-of-Blisibimod-in-Patients-with-IgA-Nephropathy.html."},{"issue":"1","key":"5267_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","volume":"390","author":"M Mathur","year":"2024","unstructured":"Mathur M, Barratt J, Chacko B, et al. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med [Internet]. 2024;390(1):20\u201331. Available from: https:\/\/doi.org\/10.1056\/NEJMoa2305635. http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2305635.","journal-title":"N Engl J Med"},{"issue":"6","key":"5267_CR37","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","volume":"105","author":"R Lafayette","year":"2024","unstructured":"Lafayette R, Barbour S, Israni R, et al. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int [Internet]. 2024;105(6):1306\u201315. Available from: https:\/\/doi.org\/10.1016\/j.kint.2024.03.012. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253824002369.","journal-title":"Kidney Int"},{"issue":"3","key":"5267_CR38","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","volume":"8","author":"J Lv","year":"2023","unstructured":"Lv J, Liu L, Hao C, et al. Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep [Internet]. 2023;8(3):499\u2013506. Available from: https:\/\/doi.org\/10.1016\/j.ekir.2022.12.014. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024922019106.","journal-title":"Kidney Int Rep"},{"issue":"8","key":"5267_CR39","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.ekir.2022.05.017","volume":"7","author":"J Barratt","year":"2022","unstructured":"Barratt J, Tumlin J, Suzuki Y, et al. Randomized phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria. Kidney Int Rep [Internet]. 2022;7(8):1831\u201341. Available from: https:\/\/doi.org\/10.1016\/j.ekir.2022.05.017. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024922014152.","journal-title":"Kidney Int Rep"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05267-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05267-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05267-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:28:39Z","timestamp":1786508919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05267-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5267"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05267-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"8 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The review protocol was prepared a priori and submitted to the International Prospective Register of Systematic Reviews (PROSPERO); registration number CRD420261456498.","order":3,"name":"Ethics","label":"Registration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"470"}}